Shared decision-making what does it mean in multiple sclerosis? Can it really help providers more fully understand their patients concerns? Can it motivate patients to more readily and enthusiastically take ownership of their disease? And most imp

As the number of new MS therapies continues to grow, so does the uncertainty about which management approach  escalation or highly effective disease-modifying therapy is best for each patient. What are the patient-specific factors t

Acomprehensive MS center what is it? Which clinicians comprise a multidisciplinary MS care team?How does comprehensiveMScarework in practice?How does it benefit patients?Thatsthe focus of this non-CME-accreditedeMultipleSclerosis Revie

The differencesin MS disease activity between children and adults.

The safety and efficacy of newly approved oral MS therapies. The differences between the induction and escalation approaches to MS treatment.

Chronic MS symptoms and their effects on quality of life.

The risk factors for postpartum MS relapses. Pregnancy planning and management strategies to moderate the risk of MS relapses.

The challenges in developing new MS therapies. The practical applications of individualizing MS therapy.

The communications issues that influence patients’ disease-modifying therapy decision-making. Potential strategies for addressing comorbidities in the clinical care of individuals with MS.

The role of emerging biomarkers, including optical coherence tomography and serum neurofilament light chain, in predicting future disability in MS.